Across TCGA pan-cancer cohorts, RPS4X Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPS4X data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher RPS4X Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS4X expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THCA, UCEC, and BLCA are the cancer types where RPS4X Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.049	0.828	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.305	.010	24	view →
BLCA	OS	Median	IV	0.211	0.602	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPS4X tumor-vs-normal RNA expression · all RPS4X data types